Literature DB >> 8181500

Successful intravenous immunoglobulin therapy for recurrent pneumococcal otitis media in young children.

A Ishizaka1, Y Sakiyama, M Otsu, K Ozutsumi, S Matsumoto.   

Abstract

Serum immunoglobulin levels and naturally occurring antibody titres against Streptococcus pneumoniae were measured in seven children aged 1-1.9 years with recurrent pneumococcal acute otitis media (AOM). Three of them had low IgG2 levels. Mean antibody levels of anti-pneumococcal IgG1 and anti-pneumococcal IgG2 were significantly lower in patients when compared to those of healthy controls and children who had less frequent episodes of AOM. Following treatment with intravenous immunoglobulin (IVIG) for 6 months, anti-pneumococcal IgG1 and IgG2 antibody levels increased and the number of episodes of AOM decreased in all patients. Following the discontinuation of IVIG therapy, no AOM episode occurred. Serum levels of anti-pneumococcal IgG1 and IgG2 were normal, which were measured in three subjects at 5, 6, and 12 months after the cessation of IVIG therapy. These results suggested that delayed maturation of anti-pneumococcal antibody production caused recurrent AOM and this condition was corrected by IVIG therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8181500     DOI: 10.1007/bf01958979

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  11 in total

Review 1.  Haemophilus influenzae infections and whooping cough.

Authors:  E R Moxon; R Rappuoli
Journal:  Lancet       Date:  1990-06-02       Impact factor: 79.321

Review 2.  Modern vaccines. Pneumococcus and influenza.

Authors:  F Shann
Journal:  Lancet       Date:  1990-04-14       Impact factor: 79.321

3.  Antibody activity of IgG subclasses against pneumococcal polysaccharides after vaccination.

Authors:  B Rynnel-Dagöö; A Freijd; K Prellner
Journal:  Am J Otolaryngol       Date:  1985 Jul-Aug       Impact factor: 1.808

4.  Immunoglobulin subclasses in normal children.

Authors:  P H Schur; F Rosen; M E Norman
Journal:  Pediatr Res       Date:  1979-03       Impact factor: 3.756

5.  Quantitation of IgG subclass antibodies to pneumococcal capsular polysaccharides by ELISA, using Pneumovax-specific antibodies as a reference.

Authors:  K Kojima; A Ishizaka; E Oshika; Y Taguchi; K Tomizawa; M Nakanishi; Y Sakiyama; S Matsumoto
Journal:  Tohoku J Exp Med       Date:  1990-07       Impact factor: 1.848

6.  Development of hypogammaglobulinaemia in a patient with common variable immunodeficiency.

Authors:  A Ishizaka; M Nakanishi; S Yamada; Y Sakiyama; S Matsumoto
Journal:  Eur J Pediatr       Date:  1989-12       Impact factor: 3.183

7.  The effect of intravenous immunoglobulin treatment in recurrent acute otitis media.

Authors:  O Kalm; K Prellner; P Christensen
Journal:  Int J Pediatr Otorhinolaryngol       Date:  1986-09       Impact factor: 1.675

8.  Clinical and immunologic characteristics of healthy children with subnormal serum concentrations of IgG2.

Authors:  P G Shackelford; D M Granoff; J V Madassery; M G Scott; M H Nahm
Journal:  Pediatr Res       Date:  1990-01       Impact factor: 3.756

9.  Gamma-globulin treatment of recurrent acute otitis media in children.

Authors:  F Jørgensen; B Andersson; L A Hanson; O Nylén; C S Edén
Journal:  Pediatr Infect Dis J       Date:  1990-06       Impact factor: 2.129

10.  Studies on human antibodies. VI. Selective variations in subgroup composition and genetic markers.

Authors:  W J Yount; M M Dorner; H G Kunkel; E A Kabat
Journal:  J Exp Med       Date:  1968-03-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Passive immunity in prevention and treatment of infectious diseases.

Authors:  M A Keller; E R Stiehm
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Successful discontinuation of immunoglobulin G replacement at age 10 in a patient with immunoglobulin G2 deficiency.

Authors:  Masayoshi Shinjoh; Yukio Sakiyama; Shinichiro Sekiguchi; Takao Takahashi
Journal:  SAGE Open Med Case Rep       Date:  2017-10-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.